News | May 23, 2026
ZIM Laboratories wins European regulatory milestone with anticoagulant approval in Italy
The approval was granted by Agenzia Italiana del Farmaco
The approval was granted by Agenzia Italiana del Farmaco
Approved product is therapeutically equivalent to Synthroid of AbbVie and is indicated for the treatment of congenital or acquired hypothyroidism
The drug is indicated for the maintenance treatment of patients with Chronic Obstructive Pulmonary Disease (COPD)
Antiviral injection addressing CMV and HSV infections had US market sales of nearly $15 million in the last 12 months
The product is bioequivalent and therapeutically equivalent to the reference listed drug by Fresenius Kabi USA, LLC.
Famotidine Injection USP is a generic version of Pepcid injection to be manufactured at its Nagpur facility for the U.S. market
Darolutamide Tablets, 300 mg, had an estimated market size of US$ 3,155 million in the United States
The CDMO segment saw a 22% decline in Q4 due to a strong base in the prior year
Fresenius Kabi's approved generic therapy addresses acute symptomatic hypocalcemia and targets a US market valued at nearly $71 million
Approval expands Lupin’s specialty portfolio in the US market for treatment of urea cycle disorders
Subscribe To Our Newsletter & Stay Updated
